In a filing, Longboard Pharmaceuticals Inc revealed its Former 10% Owner ARENA PHARMACEUTICALS INC unloaded Company’s shares for reported $96.48 million on Jan 25 ’24. In the deal valued at $24.25 per share,3,978,540 shares were sold. As a result of this transaction, ARENA PHARMACEUTICALS INC now holds 0 shares worth roughly $0.0.
Robert W. Baird initiated its Longboard Pharmaceuticals Inc [LBPH] rating to an Outperform in a research note published on May 01, 2024; the price target was $36. A number of analysts have revised their coverage, including Citigroup’s analysts, who began to cover the stock in mid February with a ‘”a Buy”‘ rating. B. Riley Securities started covering the stock on April 27, 2023. It rated LBPH as “a Buy”.
Price Performance Review of LBPH
On Tuesday, Longboard Pharmaceuticals Inc [NASDAQ:LBPH] saw its stock jump 7.01% to $22.05. Over the last five days, the stock has gained 3.50%. Longboard Pharmaceuticals Inc shares have risen nearly 265.59% since the year began. Nevertheless, the stocks have risen 143.05% over the past one year. While a 52-week high of $28.15 was reached on 01/23/24, a 52-week low of $3.60 was recorded on 01/02/24. SMA at 50 days reached $20.04, while 200 days put it at $12.40. A total of 0.32 million shares were traded, compared to the trading of 0.43 million shares in the previous session.
Levels Of Support And Resistance For LBPH Stock
The 24-hour chart illustrates a support level at 20.77, which if violated will result in even more drops to 19.50. On the upside, there is a resistance level at 22.91. A further resistance level may holdings at 23.78. The Relative Strength Index (RSI) on the 14-day chart is 58.28, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.02, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 25.79%. Stochastics %K at 64.69% indicates the stock is a holding.
The most recent change occurred on April 07, 2021 when Evercore ISI began covering the stock and recommended ‘”an Outperform”‘ rating along with a $35 price target.
